References
- Isaksson, E.; von Schoultz, E.; Odlind, V.; Soderqvist, G.; Csemiczky, G.; Carlstrom, K.; Skoog, L.; von Schoultz, B. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res. Treat. 2001, 65 (2), 163–169. [PUBMED], [INFOTRIEVE], [CSA]
- Shapiro, S.; Rosenberg, L.; Hoffman, M.; Truter, H.; Cooper, D.; Rao, S.; Dent, D.; Gudgeon, A.; van Zyl, J.; Katzenellenbogen, J.; Baillie, R. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am. J. Epidemiol. 2000, 151 (4), 396–403. [PUBMED], [INFOTRIEVE], [CSA]
- Jordan, V C.; Jeng, M H.; Catherino, W H.; Parker, C J. The estrogenic activity of synthetic progestins used in oral contraceptives. Cancer 1993, 71 (Suppl. 4), 1501–1505. [PUBMED], [INFOTRIEVE]
- Hofseth, L J.; Raafat, A M.; Osuch, J R.; Pathak, D R.; Slomski, C A.; Haslam, S Z. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J. Clin. Endocrinol. Metab. 1999, 84 (12), 4559–4565. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schairer, C.; Lubin, J.; Troisi, R.; Sturgeon, S.; Brinton, L.; Hoover, R. Menopausal estrogen and estrogen-progestins replacement therapy and breast cancer risk. JAMA 2000, 283 (4), 485–491. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ross, R K.; Paganini-Hill, A.; Wan, P C.; Pike, M C. Effect of hormonereplacement therapy on breast cancer risk: estrogen versus estrogen plus progestins. J. Natl. Cancer Inst. 2000, 92 (4), 324–332. [CROSSREF]
- Croce, M V.; Colussi, A G.; Segal-Eiras, A. Assessment of methods for primary tissue culture of human breast epithelia. J. Exp. Clin. Cancer Res. 1998, 17 (1), 19–26. [PUBMED], [INFOTRIEVE], [CSA]
- Shiue, C.; Shiue, G G.; Benard, F.; Visonneau, S.; Santoli, D.; Alavi, A A. N-(n-benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: a potential ligand for PET imaging of breast cancer. Nucl. Med. Biol. 2000, 27 (8), 763–767. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Connor, C E.; Norris, J D.; Broadwater, G.; Willson, T M.; Gottardis, M M.; Dewhirst, M W.; McDonnell, D P. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res. 2001, 61 (7), 2917–2922. [PUBMED], [INFOTRIEVE]
- Gregoraszczuk, E L.; Milewicz, T.; Kolodziejczyk, J.; Krzysiek, J.; Basta, A.; Sztefko, K.; Kurek, S.; Stachura, J. Progesterone-induced secretion of growth hormone, insulin-like growth factor-I and prolactin by human breast cancer explants. Gynecol. Endocrinol. 2001, 15 (4), 251–258. [PUBMED], [INFOTRIEVE], [CSA]
- Sakakura, T.; Nishizuka, Y.; Dawe, C K. Mesenchyme-dependent morphogenesis and epithelium-specific cytodifferentation in mouse mammary gland. Science 1976, 194 (4272), 1439–1441. [PUBMED], [INFOTRIEVE]
- Davidson, D. The function and evolution of Msx genes: pointers and paradoxes. Trends Genet. 1995, 11 (10), 405–411. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jowett, A K.; Vainio, S.; Ferguson, M W.J.; Sharpe, P T.; Thesleff, I. Epithelial-mesenchymal interactions are required for msx 1 and msx 2 gene expression in the developing murine molar tooth. Development 1993, 117 (2), 461–470. [PUBMED], [INFOTRIEVE]
- Wang, Y.; Sassoon, D. Ectoderm-mesenchyme and masenchyme-mesenchyme interaction regulate Msx-1 expression and cellular differentiation in the murine limb bud. Dev. Biol. 1995, 168 (2), 374–382. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Quinn, L M.; Latham, S E.; Kalionis, B. The homeobox genes MSX2 and MOX2 are candidates for regulating epithelial-mesenchymal cell interactions in the human placenta. Placenta 2000, 21 (Suppl. A), S50–S54. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Sarapura, V D.; Strouth, H L.; Gordon, D F.; Wood, W M.; Ridgway, E C. Msx 1 is present in thyrotropic cells and binds to a consensus site on the glycoprotein hormone alpha-subunit promoter. Mol. Endocrinol. 1997, 11 (12), 1782–1794. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Shetty, S.; Takahashi, T.; Matsui, H.; Ayengar, R.; Ragnow, R. Transcriptional autorepression of Msx 1 gene is mediated by interaction of Msx 1 protein with a multi-protein transcriptional complex containing TATA-binding protein, Sp1 and cAMP-response-element-binding protein-binding protein (CBP/p300). Biochem. J. 1999, 339 (Pt3), 751–758. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Phippard, D J.; Weber-Hall, S J.; Sharpe, P T.; Naylor, M S.; Jayatalake, H.; Maas, R.; Woo, I.; Roberts-Clark, D.; Francis-West, P H.; Liu, Y H.; Maxson, R.; Hill, R E.; Dale, T C. Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development. Development 1996, 122 (9), 2729–2737. [PUBMED], [INFOTRIEVE]
- Friedmann, Y.; Daniel, C W. Regulated expression of homeobox genes Msx-1 and Msx-2 in mouse mammary gland development suggests a role in hormone action and epithelial-stromal interactions. Dev. Biol. 1996, 177 (1), 347–355. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hu, G.; Lee, H.; Price, S M.; Shen, M M.; Abate-Shen, C. Msx homeobox genes inhibit differentiation through upregulation of cyclin D1. Development 2001, 128 (12), 2373–2384. [PUBMED], [INFOTRIEVE]
- Shinmura, K.; Sugimura, H.; Naito, Y.; Shields, P G.; Kino, I. Frequent co-occurrence of mutator phenotype in synchronous, independent multiple cancers of the stomach. Carcinogenesis 1995, 16 (12), 2989–2993. [PUBMED], [INFOTRIEVE], [CSA]
- Takahashi, T.; Guron, C.; Shetty, S.; Matsui, H.; Raghow, R. A minimal murine Msx-1 gene promoter. Organization of its cis-regulatory motifs and their role in transcriptional activation in cells in culture and in transgenic mice. J. Biol. Chem. 1997, 272 (36), 22667–22678. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Willert, J.; Epping, M.; Pollack, J R.; Brown, P O.; Nusse, R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev. Biol. 2002, 2 (1), 1–7. [CSA], [CROSSREF]
- Ahmed, S A.; Gogal, R M.; Walsh, J E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J. Immunol. Methods 1994, 170 (2), 211–224. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Nakayama, G R.; Caton, M C.; Nova, M P.; Parandoosh, Z. Assesment of the Alamar Blue assay for cellular growth and viability in vitro. J. Immunol. Methods 1997, 204 (2), 205–208. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mhashilkar, A M.; Schrock, R D.; Hindi, M.; Liao, J.; Sieger, K.; Kourouma, F.; Zou-Yang, X H.; Onishi, E.; Takh, O.; Vedvick, T S.; Fanger, G.; Stewart, L.; Watson, G J.; Snary, D.; Fisher, P B.; Saeki, T.; Roth, J A.; Ramesh, R.; Chada, S. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol. Med. 2001, 7 (4), 271–282. [PUBMED], [INFOTRIEVE]
- Schug, J.; Overton, G C. Modeling transcription factor binding sites with Gibbs sampling and minimum description length encoding. Proc. Int. Conf. Intell. Syst. Mol. Biol. 1997, 5, 268–271. [PUBMED], [INFOTRIEVE]
- Jakacka, M.; Ito, M.; Weiss, J.; Chien, P Y.; Gehm, B D.; Jameson, J L. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J. Biol. Chem. 2001, 276 (17), 13615–13621. [PUBMED], [INFOTRIEVE]
- Porter, W.; Saville, B.; Hoivik, D.; Safe, S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol. Endocrinol. 1997, 11 (11), 1569–1580. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Xie, W.; Duan, R.; Safe, S. Estrogen induces adenosine deaminase gene expression in MCF-7 human breast cancer cells: role of estrogen receptor-Sp1 interactions. Endocrinology 1999, 140 (1), 219–227. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Lapidus, R G.; Nass, S J.; Davidson, N E. The loss of estrogen and progesterone receptor gene expression in human breast cancer. J. Mammary Gland Biol. Neoplasia 1998, 3 (1), 85–94. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Min, G.; Kim, H.; Bae, Y.; Petz, L.; Kemper, J K. Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-mediated signaling pathway by squelching p160 coactivators. J. Biol. Chem. 2002, 277 (37), 34626–34633. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Oesterreich, S.; Zhang, Q P.; Lee, A V. Inhibition of oestrogen receptor activity by the corepressor HET/SAF-B is relieved by blockade of histone deacetylase activity. Eur. J. Cancer 2000, 36 (Suppl. 4), S43–S44. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Brisken, C.; Heineman, A.; Chavarria, T.; Elenbaas, B.; Tan, J.; Dey, S K.; McMahon, J A.; McMahon, A P.; Weinberg, R A. Essential function of Wnt-4 in mammary gland development downstream of progesterone signaling. Genes Dev. 2000, 14 (6), 650–654. [PUBMED], [INFOTRIEVE]
- Brentani, M M.; Franco, E L.; Oshima, C T.; Pacheco, M M. Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: a multivariate analysis approach. Int. J. Cancer 1986, 38 (5), 637–642. [PUBMED], [INFOTRIEVE]
- van der Burg, B.; Kalkhoven, E.; Isbrucker, L.; de Laat, S W. Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J. Steroid Biochem. Mol. Biol. 1992, 42 (5), 457–465. [PUBMED], [INFOTRIEVE], [CROSSREF]
- DeSombre, E R.; Jensen, E V. Cancer Medicine; Holland, J F., Frei, E., III, Bast, R C., Jr., Kufe, D W., Pollock, R E., Weichselbaum, R R., Eds.; Decker: Hamilton, ON, 2000; 706–714.
- Furr, B J.; Jordan, V C. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 1984, 25 (2), 127–205. [PUBMED], [INFOTRIEVE], [CROSSREF]
- Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998, 351 (9114), 1451–1467. [CROSSREF]
- MacGregor, J I.; Jordan, V C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 1998, 50 (2), 151–196. [PUBMED], [INFOTRIEVE]
- Jensen, E V.; Cheng, G.; Palmieri, C.; Saji, S.; Makela, S.; Van Noorden, S.; Wahlstrom, T.; Warner, M.; Coombes, R C.; Gustafsson, J A. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2001, 98 (26), 15197–15202. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]